3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Neoplasms
1
Interventions
pembrolizumab
61
Carboplatin
44
Pemetrexed
31
Paclitaxel
31
Docetaxel
31
Cisplatin
27
Gemcitabine
24
Nivolumab
23
Erlotinib Hydrochloride
21
Bevacizumab
18
Ipilimumab
11
osimertinib
10
Drug Therapy
10
atezolizumab
9
Radiosurgery
9
Cyclophosphamide
9
Cetuximab
9
Blood Specimen Collection
9
durvalumab
8
cemiplimab
8
Radiotherapy
8
budigalimab
7
Fluorouracil
7
Dexamethasone
7
trametinib
6
fludarabine
6
dostarlimab
6
avelumab
6
Taxes
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
AM0010
×
Thoracic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled